🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing around the world, with data suggesting in excess of 82 million new cases annually. Particularly high rates are observed in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the reality of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options presently on offer.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Gain Clearance

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts hope that targeted use of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GSK, gained clearance in concurrent days. This drug, which is also used to treat urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the drug firm its industry partner to develop it.

“This approval signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Data and Worldwide Availability

Based on data detailed in a prominent scientific publication, zoliflodacin cured the vast majority of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which uses an injection and a pill. The research involved hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the rights to license and sell the drug in a wide range of developing nations.

Clinicians directly involved have voiced optimism. The availability of a single-dose, oral treatment of this kind is seen as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the illness for patients and to halt the transmission of extremely resistant gonorrhoea around the world.